Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 0.0 | - |
Min SIP Amount | ₹1000 | - |
Expense Ratio | 0.93 | - |
NAV | ₹17.24 | - |
Fund Started | 25 Nov 2022 | - |
Fund Size | ₹74.96 Cr | - |
Exit Load | - | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 50.36% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
3 Year
5 Year
Equity | 99.91% | - |
Cash | 0.09% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 25.51% |
Cipla Ltd. | 11.15% |
Dr. Reddy's Laboratories Ltd. | 10.10% |
Divi's Laboratories Ltd. | 8.47% |
Lupin Ltd. | 6.47% |
Aurobindo Pharma Ltd. | 5.01% |
Alkem Laboratories Ltd. | 3.88% |
Torrent Pharmaceuticals Ltd. | 3.85% |
Zydus Lifesciences Ltd. | 3.28% |
Glenmark Pharmaceuticals Ltd. | 3.09% |
Name | Kayzad Eghlim | - |
Start Date | 03 Dec 2021 | - |
Name
Start Date
Description | The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index | - |
Launch Date | 25 Nov 2022 | - |
Description
Launch Date